Recent 8-K filings for OGN

• July 31, 2026, 8:23 AM ET other material materiality 0.50 neutral item 7.01item 9.01

  Organon furnishes supplemental non-GAAP Q2 2026 metrics; merger with Sun Pharma pending

  Company released Q2 2026 financial results via Form 10-Q, not a press release, due to pending merger with Sun Pharmaceutical Industries.

• July 23, 2026, 5:13 PM ET other material materiality 0.85 positive item 5.07

  Organon shareholders approve merger with Sun Pharma; 98.7% of votes cast in favor

  Proposal to adopt merger agreement passed with 192,776,552 votes for, 2,573,118 against, 326,189 abstaining.

• July 17, 2026, 4:01 PM ET litigation materiality 0.70 neutral item 8.01

  Organon supplements proxy with $700M synergy estimate; shareholder lawsuit seeks to delay merger vote

  Shareholder lawsuit filed July 6 in NJ Superior Court alleges proxy disclosures are materially incomplete and misleading.

• June 11, 2026, 4:15 PM ET other material materiality 0.45 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×4

  Organon stockholders approve 8M share increase to 2021 incentive plan at annual meeting

  Amended 2021 Incentive Stock Plan approved by 142.5M for, 7.6M against, 1.8M abstain; 50.8M broker non-votes.

• April 30, 2026, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01 ◈ Earnings Releases

  Organon Q1 revenue $1.46B (-4% YoY); declares $0.02 dividend; Sun Pharma merger pending

  Revenue $1.460B, down 4% as-reported, down 9% ex-FX; Women's Health -16%, Biosimilars +23%.

• April 27, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01item 5.02item 7.01item 9.01 ◈ Material Agreements

  Sun Pharma to acquire Organon for $14.00/share in all-cash deal; EV $11.75B

  Acquisition price $14.00/share in cash, a 103% premium to Organon's closing price on April 9, 2026.

• February 20, 2026, 6:59 PM ET other material materiality 0.30 positive item 8.01item 9.01

  Organon Audit Committee completes biosimilar purchase review, finds no improper conduct

  Audit Committee completed independent review of timing of biosimilar purchases from a supplier in prior years.

• February 12, 2026, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon reports FY2025 rev $6.2B (-3%), GAAP EPS $0.72; guides FY2026 rev ~$6.2B, Adj EBITDA ~$1.9B

  Full year 2025 revenue $6.2B, down 3% YoY; GAAP diluted EPS $0.72, adjusted diluted EPS $3.66.

• November 10, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon Q3 revenue $1.6B, adj. EPS $1.01; FY2025 guidance lowered

  Q3 revenue $1.602B (+1% as-reported, -1% ex-FX); net income $160M vs $359M YoY (-55%).

• November 7, 2025, 6:59 PM ET leadership materiality 0.30 neutral item 5.02

  Organon director Grace Puma will not stand for re-election at 2026 annual meeting

  Grace Puma informed Organon on Nov 3, 2025 she will not seek re-election at the 2026 Annual Meeting.

• October 30, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01

  Organon sets Executive Chair Carrie S. Cox compensation at $100,000/month

  Carrie S. Cox appointed Executive Chair effective October 26, 2025.

• October 27, 2025, 7:59 PM ET leadership materiality 0.90 negative item 5.02item 8.01item 9.01

  Organon CEO resigns after probe finds improper Nexplanon wholesaler sales; Morrissey named interim CEO

  Kevin Ali resigned as CEO and Board member; no severance or equity retirement benefits.

• August 5, 2025, 7:59 PM ET earnings materiality 0.72 positive item 2.02item 7.01item 9.01

  Organon Q2 revenue $1.594B, adj. EPS $1.00; raises FY revenue guidance to $6.275-6.375B

  Revenue $1.594B, down 1% YoY; GAAP net income $145M ($0.56 EPS); non-GAAP adj. EPS $1.00, down 11% YoY.

• June 12, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  Organon stockholders approve amended 2021 Incentive Stock Plan adding 7.8M shares

  Amended plan increases share reserve by 7.8M shares; requires 95% of awards to have minimum 1-year vesting.

• May 27, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  FDA designates Organon's HADLIMA as interchangeable biosimilar to Humira across all presentations

  FDA granted interchangeability for HADLIMA high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe.

• May 1, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 7.01item 8.01item 9.01

  Organon cuts dividend 93% to $0.08/yr; Q1 revenue down 7%, adj EPS $1.02

  Q1 revenue $1.513B, -7% as-reported (-4% ex-FX); GAAP EPS $0.33, non-GAAP adj EPS $1.02.

• April 15, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 7.01 ◈ executive_change

  Organon appoints Ramona A. Sequeira to Board of Directors

  Appointment effective July 1, 2025; Board expands to 12 directors.

• February 13, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon FY2024 revenue $6.4B (+2%); guides FY2025 revenue $6.125-6.325B

  Full year 2024 revenue $6,401M (+2% as-reported, +3% constant currency); diluted EPS $3.33; non-GAAP adjusted diluted EPS $4.11.

• January 21, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

  Organon CCO Susanne Fiedler departs effective Jan 15, senior advisor until April 30

  Susanne Fiedler ceased performing CCO functions effective January 15, 2025.

• December 23, 2024, 6:59 PM ET other materiality 0.20 neutral item 8.01

  Organon board reduces size to 11 after director McGarry's resignation

  Director Martha E. McGarry resigned from the board; resignation previously announced.

• December 6, 2024, 6:59 PM ET leadership materiality 0.20 neutral item 5.02

  Director Martha E. McGarry resigns from Organon Board effective December 4, 2024

  Martha E. McGarry notified the Board of her resignation effective December 4, 2024.

• November 5, 2024, 6:59 PM ET regulatory materiality 0.60 neutral item 7.01item 9.01

  FDA extends VTAMA sNDA review for atopic dermatitis to March 12, 2025

  FDA extended target action date by 3 months to March 12, 2025; original date was December 12, 2024.

• October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Organon Q3 revenue $1.582B (+4% YoY); narrows FY revenue guidance upward to $6.375-6.425B

  GAAP diluted EPS $1.38; non-GAAP adjusted diluted EPS $0.87 (includes $0.16 IPR&D charge).

• September 23, 2024, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 9.01

  Organon acquires Dermavant Sciences for up to $1.2B; VTAMA drug portfolio

  Total consideration up to $1.2B: $175M upfront, $75M FDA milestone for atopic dermatitis, up to $950M commercial milestones.

• August 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Organon Q2 2024 revenue flat at $1.607B; Adj. EPS $1.12, down 15% YoY

  Revenue $1.607B flat YoY (up 2% constant currency); net income $195M vs $242M prior year.

• June 6, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Organon shareholders elect all four Class III directors, approve say-on-pay and auditor ratification

  All four Class III director nominees elected: Kevin Ali, Martha E. McGarry, Philip Ozuah, Shalini Sharp each received >173M votes for.

• May 17, 2024, 7:59 PM ET debt materiality 0.75 neutral item 1.01item 2.03item 9.01 ◈ Material Agreements ×2

  Organon issues $1B in senior notes, amends credit facilities to extend maturities and reduce rates

  Issued $500M 6.750% senior secured notes due 2034 and $500M 7.875% unsecured notes due 2034.

• May 2, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Organon Q1 2024 revenue up 5% to $1.62B; adjusted EPS $1.22, up 13% YoY; 2024 guidance reaffirmed

  Q1 revenue $1,622M (+5% as-reported, +7% constant currency); net income $201M (+14% YoY).

• February 15, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Organon Q4 revenue $1.60B (+8% YoY); FY23 EPS $3.99; FY24 guidance $6.2-6.5B

  FY23 revenue $6.3B (+1% as-reported, +3% constant currency).

• December 5, 2023, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

  Organon R&D Head Sandra Milligan to depart Jan 5; ceased role Dec 1

  Dr. Sandra Milligan, Head of Research and Development, will leave Organon on January 5, 2024.

• November 2, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Organon Q3 revenue $1.52B, adj. EPS $0.87; narrows & lowers FY2023 guidance

  Revenue $1,519M (-1% YoY); diluted EPS $0.23; non-GAAP adj. diluted EPS $0.87.

• August 8, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Organon Q2 2023 revenue $1.61B (+4% ex-FX); adj. EPS $1.31; FY guidance narrowed

  GAAP diluted EPS $0.95; non-GAAP adjusted diluted EPS $1.31 vs $1.25 prior year.

• July 7, 2023, 7:59 PM ET debt materiality 0.15 neutral item 1.01item 2.03item 9.01 ◈ Material Agreements

  Organon amends credit agreement to replace LIBOR with SOFR-based rates

  Amendment replaces LIBOR with Adjusted Term SOFR in senior secured credit agreement dated June 2, 2021.

• June 8, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Organon shareholders elect all Class II directors, approve say-on-pay, ratify auditor

  All four Class II directors elected: Carrie S. Cox, Alan Ezekowitz, Helene Gayle, Deborah Leone.

• May 4, 2023, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 7.01item 9.01

  Organon Q1 revenue $1.54B, net income $177M (-49%), adjusted EPS $1.08

  Revenue of $1,538M, down 2% as-reported but up 3% ex-FX vs Q1 2022; all three franchises grew on constant currency basis.

• February 16, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Organon reports FY 2022 revenue $6.2B (-2% as-reported); Q4 GAAP EPS $0.42, provides 2023 guidance

  FY 2022 revenue $6.174B, down 2% as-reported, up 4% ex-FX; diluted GAAP EPS $3.59, non-GAAP adjusted $5.03.

• December 9, 2022, 6:59 PM ET other materiality 0.10 neutral item 3.03item 5.03item 9.01 ◈ Governance Changes

  Organon amends bylaws to adopt universal proxy card rules

  Board approved Amended and Restated Bylaws effective December 6, 2022, to comply with Rule 14a-19.

• November 3, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Organon Q3 revenues $1.54B (-4% YoY); raises FY adjusted EBITDA margin guidance

  Q3 revenue $1,537M, down 4% YoY as-reported but up 3% ex-FX.

• August 4, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Organon Q2 revenues $1.585B (-1% as-reported, +5% ex-FX); adj EPS $1.25; FY guidance narrowed

  Q2 revenues $1,585M, down 1% as-reported but up 5% ex-FX vs Q2 2021; diluted EPS $0.92, adj diluted EPS $1.25 (both include -$0.30 IPR&D).

• July 12, 2022, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 ◈ executive_change

  Organon General Counsel Deborah Telman resigns effective July 22, 2022

  EVP, General Counsel and Corporate Secretary Deborah H. Telman resigned on July 7, 2022.

• June 8, 2022, 7:59 PM ET other material materiality 0.10 neutral item 5.07

  Organon shareholders elect four Class I directors and approve say-on-pay at 2022 annual meeting

  Class I directors Robert Essner, Shelly Lazarus, Cynthia M. Patton, Grace Puma elected with >96% of votes cast.

• May 6, 2022, 7:59 PM ET earnings materiality 0.50 neutral item 7.01item 9.01

  Organon held Q1 2022 earnings call; financial results not provided in excerpt

  Company held conference call on May 5, 2022 to discuss Q1 2022 results.

• May 5, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Organon Q1 revenue $1.567B (+8% ex-FX); adj. EPS $1.65; reaffirms FY guidance

  Revenue $1,567M, +4% as-reported / +8% ex-FX vs Q1 2021; Women's Health -5%, Biosimilars +22%, Established Brands +10%.

• February 17, 2022, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Organon FY21 rev $6.3B, adj. EPS $6.54; provides FY22 guide rev $6.1-$6.4B, adj. EBITDA margin 34-36%

  FY21 revenue $6.3B (-3% as-reported vs 2020); GAAP diluted EPS $5.31; non-GAAP adj. diluted EPS $6.54.

• November 12, 2021, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Organon Q3 revenue $1.6B (-1% YoY); adj. EPS $1.67; FY guidance narrowed; dividend $0.28

  Revenue $1,600M, down 1% as-reported and 3% ex-FX YoY; net income from continuing ops $323M ($1.27 diluted EPS).

• August 12, 2021, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Organon Q2 2021 revenue $1.6B, net income $431M; declares inaugural $0.28 quarterly dividend

  Q2 2021 revenue $1,595M (+5% as-reported; -1% ex-FX); Women's Health +19%, Biosimilars +43%, Established Brands -4%.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.68 · Most common event earnings

8 positive 8 negative 30 neutral

source · OGN on sec.gov